Ahead of the FDA Oncologic Drugs Advisory Committee meeting, regulators released briefing documents raising concerns over GSK’s antibody-drug conjugate Blenrep's ocular toxicity and uncertain safe dosing. While recent trial data demonstrated efficacy when combined with other therapies for relapsed or refractory multiple myeloma, reviewers highlighted high rates of severe eye-related adverse events and questioned dose optimization. Blenrep was withdrawn in 2022 after a confirmatory trial failed to meet survival endpoints, and the FDA remains cautious about its benefit-risk profile.